Tag: release

Transaction brings total financing commitments across Alterra’s fully discretionary IOS funds to over $1.5 billion

Rehovot, Israel, July 16, 2025 (GLOBE NEWSWIRE) -- Steakholder Foods Ltd. (Nasdaq: STKH) (“Steakholder Foods” or the “Company”), a leading innovator in alternative proteins and 3D printing technologies, today announced the pricing of a public offering of an aggregate of 2,380,954 of the Company’s American Depository Shares (“ADSs”), each representing five hundred (500) ordinary shares of the Company (or ADS equivalents in lieu thereof), and accompanying warrants to purchase up to 2,380,954 of the Company’s ADSs, at a combined public offering price of $1.05 per ADS (or ADS equivalent in lieu thereof) and associated warrant. The warrants will have an exercise price of $1.05 per ADS, will be exercisable immediately upon issuance and will expire on the five-year anniversary of the issuance date. The closing of the offering is expected to occur on or about July 17, 2025, subject to the satisfaction of customary closing conditions. 

ASHBURN, Va., July 16, 2025 (GLOBE NEWSWIRE) -- Verizon Frontline today announced that two more industry partners have joined the growing list of companies whose products have earned “Verizon Frontline Verified” status. With Radiav and Siyata now part of the "Verizon Frontline Verified" program, Verizon continues to demonstrate its commitment to providing proven 5G-enabled solutions built for first responders.

SUNNYVALE, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that Henry Ford Health in Detroit, Michigan is now enrolling patients with ischemic HFrEF in the Company’s ongoing pivotal CardiAMP HF II trial.

PALM BEACH, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Worldwide, there is a growing demand for cryptocurrency payments applications. A report from Grand View Research projected that the global cryptocurrency payment apps market size was estimated at USD 556.9 million in 2024 and is projected to reach USD 2,404.1 million by 2033, growing at a CAGR of 17.8% from 2025 to 2033. The emergence of Web3 and blockchain technology created the need for cryptocurrency payment apps to enable individuals to conduct seamless transactions. The report said: “The growing adoption of cryptocurrencies globally is the key driver for the market's expansion. People are encouraged to use cryptocurrency payment platforms owing to the decentralized nature of the blockchain, which eliminates mediators such as banks from the payment processing system. It reduces the processing time and accelerates the transaction speed, consequently adding to the increasing popularity of such platforms. In addition, the growing prevalence of cryptocurrencies as an investment option among millennials is also fueling the growth of the cryptocurrency payment apps industry.” It continued: “One of the most transformative trends in the market is the increasing interoperability between crypto payment platforms and traditional banking systems. Crypto apps now allow users to seamlessly convert digital assets into fiat currencies and vice versa, enabling easier withdrawals, direct-to-bank transfers, and debit card functionalities. This fusion is bridging the gap between old and new financial infrastructures, encouraging a smoother transition for users hesitant to move entirely into decentralized finance (DeFi). Thus, increasing integration of cryptocurrency payment apps with traditional financial systems can be attributed to the market’s growth.” Active companies in the markets this week include Amaze Holdings, Inc. (NYSE American: AMZE), Shopify Inc. (NASDAQ: SHOP), Roblox Corporation (NYSE: RBLX), PayPal Holdings, Inc. (NASDAQ: PYPL), Hut 8 Corp. (NASDAQ: HUT).

NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group," “Aptorum” or the "Company"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs in oncology  and infectious diseases, and DiamiR Biosciences (“DiamiR”), a developer of proprietary innovative blood-based tests for brain health and other diseases with a CLIA licensed, CAP accredited clinical laboratory in New Haven, CT, today announced that they have entered into a definitive agreement for an all-stock merger transaction, in which DiamiR Biosciences will retain its name and become a wholly-owned subsidiary of Aptorum Group upon consummation of the merger.The combined company expects to remain listed on the Nasdaq Stock Market following the closing of the merger.

Jackbit announces new casino welcome offer with 100 free spins and no wagering requirements. Read how it unfolds for casino players in 2025.